• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Kendle Reports 78% Drop in Profits, Begins Cost-Saving Efforts

Kendle Reports 78% Drop in Profits, Begins Cost-Saving Efforts

May 7, 2009
CenterWatch Staff

Cincinnati-based contract research organization (CRO) Kendle warned investors earlier this month that first quarter 2009 profits would be down, and down they are.

The company reported net income of $886,000 or $0.06 per share for the first quarter 2009, compared with net income of $4.1 million or $0.27 per diluted share for the same period last year. Net service revenues for the quarter totaled $108.1 million, compared with $1.14 million in the first quarter 2008.

Kendle chairman and CEO Candace Kendle warned shareholders earlier this month that first quarter revenues would be significantly lower than original forecasts. That news caused the company’s shares to plummet more than 50%. Following the company’s earnings release yesterday, Kendle’s share price increased in after-hours trading by half a percentage point to $9.61.

To cut costs, Kendle has implemented strict controls over discretionary spending, a hiring and wage freeze and “workforce optimization initiatives.”  The company said it plans to reorganize its leadership structure, ultimately saving between $17.5 million and $22.5 million in the second half of 2009.

“We are taking aggressive steps to enhance our business development efforts, realign our leadership and organizational structure and implement a series of margin improvement and cost reduction initiatives to move our business to the next level,” Kendle said in a company statement.

Senior vice president and chief financial officer (CFO) and secretary Karl “Buzz” Brenkert III abruptly left the CRO last week, after six years as CFO. He was replaced by Kendle’s vice president of accounting Keith Cheesman.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing